title: Beneficial Effects of Reconstituted High-Density Lipoprotein (rHDL) on Circulating CD34+ Cells in Patients after an Acute Coronary Syndrome.
abstract: BACKGROUND
  High-density lipoproteins (HDL) favorably affect endothelial progenitor cells (EPC). Circulating progenitor cell level and function are impaired in patients with acute coronary syndrome (ACS). This study investigates the short-term effects of reconstituted HDL (rHDL) on circulating progenitor cells in patients with ACS.
  
  
  RESULTS
  The study population consisted of 33 patients with recent ACS: 20 patients from the ERASE trial (randomized to receive 4 weekly intravenous infusions of CSL-111 40 mg/kg or placebo) and 13 additional patients recruited as controls using the same enrolment criteria. Blood was collected from 16 rHDL (CSL-111)-treated patients and 17 controls at baseline and at 6-7 weeks (i.e. 2-3 weeks after the fourth infusion of CSL-111 in ERASE). CD34+ and CD34+/kinase insert domain receptor (KDR+) progenitor cell counts were analyzed by flow cytometry. We found preserved CD34+ cell counts in CSL-111-treated subjects at follow-up (change of 1.6%), while the number of CD34+ cells was reduced (-32.9%) in controls (p = 0.017 between groups). The level of circulating SDF-1 (stromal cell-derived factor-1), a chemokine involved in progenitor cell recruitment, increased significantly (change of 21.5%) in controls, while it remained unchanged in CSL-111-treated patients (p = 0.031 between groups). In vitro exposure to CSL-111 of early EPC isolated from healthy volunteers significantly increased CD34+ cells, reduced early EPC apoptosis and enhanced their migration capacity towards SDF-1.
  
  
  CONCLUSIONS
  The relative increase in circulating CD34+ cells and the low SDF-1 levels observed following rHDL infusions in ACS patients point towards a role of rHDL in cardiovascular repair mechanisms.
authors.affiliation: Montreal Heart Institute, Montreal, Quebec, Canada.|Université de Montréal, Montreal, Quebec, Canada.
authors.forename: Catherine
authors.initials: C
authors.lastname: Gebhard
authors.affiliation: Montreal Heart Institute, Montreal, Quebec, Canada.|Université de Montréal, Montreal, Quebec, Canada.
authors.forename: Eric
authors.initials: E
authors.lastname: Rhéaume
authors.affiliation: Montreal Heart Institute, Montreal, Quebec, Canada.|Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom.
authors.forename: Colin
authors.initials: C
authors.lastname: Berry
authors.affiliation: Montreal Heart Institute, Montreal, Quebec, Canada.
authors.forename: Geneviève
authors.initials: G
authors.lastname: Brand
authors.affiliation: Montreal Heart Institute, Montreal, Quebec, Canada.
authors.forename: Anne-Elen
authors.initials: AE
authors.lastname: Kernaleguen
authors.affiliation: Montreal Heart Institute, Montreal, Quebec, Canada.
authors.forename: Gabriel
authors.initials: G
authors.lastname: Théberge-Julien
authors.affiliation: Montreal Heart Institute, Montreal, Quebec, Canada.
authors.forename: Mohammad Afaque
authors.initials: MA
authors.lastname: Alam
authors.affiliation: Montreal Heart Institute, Montreal, Quebec, Canada.
authors.forename: Candace Y W
authors.initials: CY
authors.lastname: Lee
authors.affiliation: Montreal Heart Institute, Montreal, Quebec, Canada.|Université de Montréal, Montreal, Quebec, Canada.
authors.forename: Laurianne
authors.initials: L
authors.lastname: Boileau
authors.affiliation: Montreal Heart Institute Coordinating Centre (MHICC), Montreal, Quebec, Canada.
authors.forename: Malorie
authors.initials: M
authors.lastname: Chabot-Blanchet
authors.affiliation: Montreal Heart Institute Coordinating Centre (MHICC), Montreal, Quebec, Canada.
authors.forename: Marie-Claude
authors.initials: MC
authors.lastname: Guertin
authors.affiliation: Montreal Heart Institute, Montreal, Quebec, Canada.|Université de Montréal, Montreal, Quebec, Canada.
authors.forename: Marc-André
authors.initials: MA
authors.lastname: Lavoie
authors.affiliation: Montreal Heart Institute, Montreal, Quebec, Canada.|Université de Montréal, Montreal, Quebec, Canada.
authors.forename: Jean
authors.initials: J
authors.lastname: Grégoire
authors.affiliation: Montreal Heart Institute, Montreal, Quebec, Canada.|Université de Montréal, Montreal, Quebec, Canada.
authors.forename: Réda
authors.initials: R
authors.lastname: Ibrahim
authors.affiliation: Montreal Heart Institute, Montreal, Quebec, Canada.|Université de Montréal, Montreal, Quebec, Canada.
authors.forename: Philippe
authors.initials: P
authors.lastname: L'Allier
authors.affiliation: Montreal Heart Institute, Montreal, Quebec, Canada.|Université de Montréal, Montreal, Quebec, Canada.
authors.forename: Jean-Claude
authors.identifier: http://orcid.org/0000-0002-8200-8983
authors.initials: JC
authors.lastname: Tardif
mesh_terms: D054058:Acute Coronary Syndrome / Q000188:drug therapy*; D018952:Antigens, CD34; D002448:Cell Adhesion / Q000187:drug effects; D002465:Cell Movement / Q000187:drug effects; D008076:Cholesterol, HDL / Q000627:therapeutic use*; D066026:Endothelial Progenitor Cells / Q000187:drug effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010713:Phosphatidylcholines / Q000627:therapeutic use*
chemical_list: D018952:Antigens, CD34; C519043:CSL-111; D008076:Cholesterol, HDL; D010713:Phosphatidylcholines